The Global Generic Injectable Market is projected to reach a valuation of US$ 322.43 Billion by 2033 | Future Market Insights, Inc.

Increase in Upfront Investments for the Development of Generic Injectables to Generate Bright Prospects for Market Growth: Market is Anticipated to Expand at 11.6% CAGR. The United States is expected to dominate the generic injectable market throughout the forecast period


NEWARK, Del, March 14, 2023 (GLOBE NEWSWIRE) -- The global generic injectable market is predicted to register a robust CAGR of 11.6% over the forecast period, as per FMI’s analysis. The industry’s size is anticipated to increase from US$ 1,07,419.72 million in 2023 to US$ 3,22,433.1 million by 2033 end.

The rising geriatric population, along with the prevalence of chronic diseases, is projected to have a favorable impact on the growth of the generic injectable industry. The research and development cycles of generic drugs are less than their bio-equivalents of branded counterparts. This offers time efficiency to the manufacturers and helps bolster the demand for generic injectables. Additionally, the low-cost related to the manufacturing of generic injectables are also luring new companies to enter the market arena and drive market growth.

The development of generic injectables is further being augmented by the rising adoption of advanced technologies, increasing population, and the execution of favorable government regulations. Significant upfront investments to augment the manufacturing process is anticipated to enhance the generic injectable industry. Moreover, key players in the market are focusing on extending their footprint in emerging economies like China and India, which are expected to have a positive influence over the market in the years to come.

Get the Latest Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-6051

Top Highlights from the FMI’s Analysis of the Generic Injectable Market:

  • The United States is projected to stand at the pinnacle of generic injectable market growth over the upcoming years. The United States is expected to attain US$ 87,936.2 million by 2033, registering a CAGR of 11.2% in the meanwhile.
  • China market is slated to be second in line, attaining US$ 36,419.2 million by 2033. The market is anticipated to exhibit a 14.5% CAGR over the next 10 years.
  • In the North America market, Canada is expected to reach US$ 4,480 million by 2033. Over the forecast period, the market is projected to assume a CAGR of 7.2%.
  • In the Europe region, Germany is anticipated to acquire a significant regional market share. Germany market is estimated to obtain US$ 24,393.1 million by 2033. From 2023 to 2033, the market is projected to expand at 13.4% CAGR.
  • The United Kingdom market is projected to attain a market valuation of US$ 18,035.5 million by 2033. Over the forecast period, the market is assessed to register a CAGR of 11.1%.
  • On the basis of molecule, the large molecule segment is projected to observe significant growth. Over the upcoming years, the market is perceived to expand at 13.2% CAGR, up from the 12.6% CAGR observed in the historical period.
  • Based on application, infectious diseases are projected to witness significant traction in the years to come. The segment is projected to expand at a CAGR of 10.8% in the forecast period.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-6051

Key Developments Stirring Up the Marketplace

  • In October 2022, Alembic Pharmaceuticals received concluding approval from the United States health regulatory body. The approval has been given for its generic version of Paclitaxel injection which is used in the treatment of various types of cancer. The company stated in its regulatory filing that this is the first product consent provided for oncology injection.

  • In February 2020, Samsung Biologics declared that it is going to expand its manufacturing, after clocking a 64.6% growth in operating profits and 30.9% growth in sales.

Some Leading Companies Operating in the Market are

  • Samsung Biologics Co Ltd
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Merck & Co. Inc.
  • Cipla Ltd
  • Pfizer Inc
  • Fresenius Kabi
  • Sanofi S.A
  • AstraZeneca Plc

Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-6051

Generic Injectable Market by Category

By Product type:

  • Monoclonal Antibodies
  • Immunoglobulin
  • Cytokines
  • Insulin
  • Peptide Hormones
  • Blood Factors
  • Peptide Antibiotics
  • Vaccines
  • Small Molecule Antibiotics
  • Chemotherapy Agents
  • Others

By Molecule Type:

  • Small Molecule
  • Large Molecule
  • By Application:
  • Oncology
  • Infectious Diseases
  • Diabetes
  • Blood Disorders
  • Hormonal Disorders
  • Musculoskeletal Disorders
  • CNS Diseases
  • Pain Management
  • Cardiovascular Diseases

By Route of Administration:

  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)

By Distribution channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa

Table of Content

1. Executive Summary | Generic Injectable Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

Browse Full Report @ https://www.futuremarketinsights.com/reports/generic-injectable-market

Explore FMI’s Extensive Coverage On Healthcare Domain:

Multi-Functional Point Of Care Testing Market Demand: Point of Care testing, often known as with-patient testing, is a pathology service that enables doctors and other medical personnel to carry out diagnosing utilising IVDs such analyzers and test kits.

Dental Imaging Equipment Market Share : The market for dental imaging equipment is anticipated to grow from a projected valuation of US$ 2.99 Bn in 2021 to US$ 5.91 Bn by 2030, expanding at a CAGR of 7.9%.

Phototherapy Lamps Market Growth : By the end of 2022, the market for phototherapy lights is projected to be worth US$ 3.2 Billion, up from US$ 3.0 Billion in 2021. Between 2022 and 2032, the global market for phototherapy lights is anticipated to increase at a CAGR of 5.8%, reaching a value of $5.6 Bn.

Spinal Fusion Market Size : By the end of 2022, the global spinal fusion market is projected to be worth US$9.49 billion. From 2022 to 2032, the market is anticipated to continue to grow at a CAGR of 5.5%. By the end of 2032, its value is forecast to reach US$ 16.2 Billion.

Membrane Microfiltration Market Opportunity : Current advancements in the market for membrane microfiltration indicate that the sector is expected to produce US$ 5,096.5 Mn in 2022 and is predicted to grow at a positive CAGR of 7.9% between 2022 and 2028 to reach US$ 8,048.5 Million.

About Future Market Insights, Inc :

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedInTwitterBlogsYouTube
For Sales Enquiries: sales@futuremarketinsights.com